The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
HOME > BUSINESS
BUSINESS
- Kissei to Spice Up Current Portfolio in Next 3 Years, Launch New Drugs Later
October 1, 2014
- Takeda, MacroGenics Sign Second Agreement to Develop Autoimmune Disease Treatments
October 1, 2014
- Sumitomo Dainippon’s FY2013 Payments to Healthcare Professionals at 13.1 Billion Yen
October 1, 2014
- Kyowa Kirin, Pfizer to Collaborate on Cancer Immunotherapy
October 1, 2014
- Kowa Receives Approval for Glaucoma Treatment Glanatec
October 1, 2014
- AZ Was Concerned with Pfizer’s Possible Takeover Deal Withdrawal Due to US Anti-Inversion Move: CEO
September 30, 2014
- e-Detailing Powerhouse M3 to Establish New Firm Dedicated to CSO Biz
September 30, 2014
- Lixiana OK’d for Stroke Prevention in Japan: Daiichi Sankyo
September 30, 2014
- Daiichi Sankyo to Buy US Biotech Ambit, Beef Up Oncology Portfolio
September 30, 2014
- Kyowa Kirin’s Neutropenia Treatment G-Lasta Approved
September 30, 2014
- JCR Files NDA for Japan’s 1st Cell-Based Drug JR-301
September 30, 2014
- Sumitomo Dainippon, SanBio to Jointly Develop Cell Therapy Agent for Chronic Stroke in North America
September 30, 2014
- Ixekizumab Improves Skin Lesions in Japanese Psoriasis Patients: Eli Lilly Japan
September 30, 2014
- Avigan Administered to Ebola-Infected French Woman: Fujifilm
September 29, 2014
- Sanofi’s 2013 Payments to Healthcare Professionals Down 11%
September 29, 2014
- Novartis Files Panobinostat for Multiple Myeloma in Japan
September 29, 2014
- Sanofi Opens Asia Pacific Development Hub in Shanghai
September 29, 2014
- Ribomic Goes Public, Aims to Swing to Black on Aptamers
September 26, 2014
- NBI Paid 14.6 Billion Yen to Healthcare Professionals in 2013
September 26, 2014
- Takeda to Invest 2.5 Billion Yen in US Firm for New Drug Development
September 26, 2014
ページ
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…